| __timestamp | Apellis Pharmaceuticals, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 675200000 |
| Thursday, January 1, 2015 | 6356782 | 771800000 |
| Friday, January 1, 2016 | 4303743 | 1205500000 |
| Sunday, January 1, 2017 | 10463151 | 1146500000 |
| Monday, January 1, 2018 | 22639184 | 1125800000 |
| Tuesday, January 1, 2019 | 67046483 | 1166100000 |
| Wednesday, January 1, 2020 | 139401000 | 1175500000 |
| Friday, January 1, 2021 | 176771000 | 1111400000 |
| Saturday, January 1, 2022 | 277163000 | 1210100000 |
| Sunday, January 1, 2023 | 500815000 | 1274600000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Apellis Pharmaceuticals, Inc. and Perrigo Company plc offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Apellis saw a staggering increase in SG&A expenses, skyrocketing from approximately $2.9 million to over $500 million, marking a growth of over 17,000%. Meanwhile, Perrigo's expenses remained relatively stable, with a modest increase of about 89%, from $675 million to $1.27 billion.
This divergence highlights differing strategic approaches: Apellis's rapid expansion and investment in administrative capabilities versus Perrigo's steady, controlled growth. Understanding these trends provides valuable insights into how companies navigate financial management in a dynamic industry. As investors and stakeholders, recognizing these patterns can inform better decision-making and strategic planning.
Takeda Pharmaceutical Company Limited vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: argenx SE vs Apellis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Apellis Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated and Perrigo Company plc: SG&A Spending Patterns Compared
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Bausch Health Companies Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Evotec SE
Viking Therapeutics, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.